An Open-label, Randomized, Single-dose, Oral Administration, 2-sequence, 2-period, Crossover Study to Evaluate Bioequivalence Between YHP2205 and YHR2401 in Healthy Subjects
Latest Information Update: 22 Jul 2024
At a glance
- Drugs YHP 2205 (Primary) ; YHR 2401 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Yuhan ANZ
- 12 Jul 2024 Status changed from not yet recruiting to completed.
- 09 May 2024 Planned End Date changed from 24 Jul 2024 to 6 Jul 2024.
- 09 May 2024 Planned primary completion date changed from 19 Jul 2024 to 1 Jul 2024.